15 February 2023
08 January 2018
Incoming: Spare Slots for Freelance Work in 2018
Posted by Glyn Moody at 10:08 am 0 comments
Labels: ceta, china, copyright, encryption, europe, free software, freedom of speech, open access, open data, open science, open source, patents, privacy, surveillance, tisa, tpp, trade secrets, TTIP
29 July 2014
The European Commission's Great TTIP Betrayal
Let me be clear on this very important point: we are not lowering standards in TTIP. Our standards on consumer protection, on the environment, on data protection and on food are not up for negotiation. There is no “give and take” on standards in TTIP.
Simple logic tells us that this can't possibly be true. If two completely different regulatory systems are to be brought together - the avowed aim of TTIP - there are only three possibilities. Either the side with the higher standards levels down; the side with the lower standards levels up; or there is mutual recognition of each other's standards. The US has clearly stated that it is not prepared to level up - it won't accept EU bans on chlorine-washed chickens, hormone beef or GMOs.
Mutual recognition, although apparently different, is in fact identical to levelling down: if both regulations are acceptable, manufacturers working to the higher set will be at a disadvantage commercially. They will therefore either relocate their factories to the country with the lower standards, which are cheaper to implement, or lobby for the higher standards to be levelled down, threatening either to leave the country, or shut down. Politicians always give in to this kind of blackmail, so EU standards would inevitably be lowered to those of the US as a result of mutual recognition.
But it has become increasingly clear that there is another way for the European Commission to circumvent its own promises that TTIP will not lower standards. The trick here is that the European Commission will lower standards *before* TTIP; so technically speaking it is not TTIP that brings about that dilution - it occurred "independently". Thus the Commission will be able to put its hand on its heart and swear blind that it kept its word not to sell out EU standards in TTIP, while at the same time changing the regulatory context in such a way that the US will be able to export things that are currently banned by strict EU legislations.
We're seeing more and more examples of this. Here, for example, is how new GMO regulations will allow US companies to bring in GM food:
Genetically modified crops could be grown in the UK from next year after the EU ministers relaxed laws on the controversial farming method.
Maize that has been engineered to resist weedkiller is the first to be approved but all commercial GM crops will not be given the green light for another 10 years.
Owen Patterson, the Environment Secretary, has long supported the introduction of GM crops in the UK and voted in favour of the changes on Thursday.
He said: “This is a real step forward in unblocking the dysfunctional EU process for approving GM crops, which is currently letting down our farmers and stopping scientific development.
Here's how the EU's Fuel Quality Directive, designed to discourage the use of highly-polluting carbon fuels, is being drastically weakened [.pdf]:
Since its inception in 2009, the Fuel Quality Directive (FQD), a European Union regulation aimed at reducing the climate impact of transport fuels, has been attacked by powerful lobby interests that do not want the EU to take action to curtail the use of particularly greenhouse gas intensive fossil fuels.
...
these attempts to weaken this landmark climate policy seem to have been successful. If recent media reports are correct, the European Commission has decided to significantly weaken the FQD and align its regulatory standards with the wishes of the oil industry, the US trade negotiators [for TTIP] and the Canadian government. Compared to a previous proposal from 2011, it would be considerably less effective in cleaning up Europe’s transport fuels and preventing the most climate polluting fuels, including tar sands, from entering Europe.
Most recently, we have learned that the European Commission is preparing to allow endocrine disruptors in pesticides - another key demand from the US side in TTIP. Unfortunately, the source for this information, Inside US Trade, is behind a paywall, so I can't give a link, but will just quote a couple of key passages:
One of the options proposed by the commission in a June 17 "roadmap" is to shift from the current EU approach of banning the use of all endocrine disruptors in pesticides toward a model that could allow them to be used as long as certain steps are taken to mitigate the risk.
This risk assessment-based model is favored by the U.S. and EU pesticide industries and is the approach employed under the U.S. Environmental Protection Agency's "Endocrine Disruptor Screening Program." Such a model seeks to evaluate both whether a hazard exists and if it can be mitigated by limiting exposure, in order to allow the marketing of an otherwise dangerous product.
As you can see, this amounts to abandoning the EU's Precautionary Principle, and adopting the completely different risk-based approach of the US. Aside from the fact that this shows that the European Commission's promises that standards would not fall, that the EU would not be forced to adopt US approaches, and that public health in Europe would always be safeguarded, were worthless, this also disregards the EU's Treaty of Lisbon, which explicitly states:
Union policy on the environment shall aim at a high level of protection taking into account the diversity of situations in the various regions of the Union. It shall be based on the precautionary principle and on the principles that preventive action should be taken, that environmental damage should as a priority be rectified at source and that the polluter should pay.
Criticial future research on the plight of bees risks being tainted by corporate funding, according to a report from MPs published on Monday. Pollinators play a vital role in fertilising three-quarters of all food crops but have declined due to loss of habitat, disease and pesticide use. New scientific research forms a key part of the government’s plan to boost pollinators but will be funded by pesticide manufacturers.
“When it comes to research on pesticides, the Department of Environment, Food and Rural Affairs (Defra) is content to let the manufacturers fund the work,” said EAC chair Joan Walley. “This testifies to a loss of environmental protection capacity in the department responsible for it. If the research is to command public confidence, independent controls need to be maintained at every step. Unlike other research funded by pesticide companies, these studies also need to be peer-reviewed and published in full”.
Posted by Glyn Moody at 9:41 am 0 comments
Labels: endocrine disruptor, european commission, fuel quality directive, gmos, isds, karel de gucht, open data, owen paterson, pesticides, policy, precautionary principle, science-based, TAFTA, tainted, TTIP
24 July 2014
Why Opening Up Clinical Trials Data Is Good For Pharma Companies Too
Earlier this year we wrote about how AbbVie, the pharma company spun out of Abbott Laboratories, had gone to court to stop the European Medicines Agency (EMA) from releasing clinical trials information about one of its drugs. Despite what AbbVie claimed, this was not commercially sensitive in any way, but simply basic data about safety and efficacy.
On Techdirt.
Posted by Glyn Moody at 1:24 pm 0 comments
Labels: abbvie, clinical trials, open data, pharma, techdirt
24 November 2013
Of Surveillance Debates and Open Clinical Data
Revelations about the staggering levels of online surveillance that are now routine in this country have been met with a stunning silence from the UK government. There's an important meeting tomorrow where three MPs from the main parties are trying to get some kind of debate going on this crucial issue. It would be helpful if you could ask your MP to participate. Here's what I've written:
On Open Enterprise blog.
Posted by Glyn Moody at 8:00 pm 0 comments
Labels: clinical trials, open data, open enterprise, surveillance
Open Clinical Trials: Please Write to Health Minister
I first wrote about the importance of open clinical trials two years ago. More recently, I urged people to contact their MEPs for a crucial vote that was taking place in one of the committees in the European Parliament. The AllTrials site, which is coordinating the fight to obtain access to this vital public health information, now asks for help during another stage in the battle for open data:
On Open Enterprise blog.
Posted by Glyn Moody at 7:58 pm 0 comments
Labels: alltrials, clinical trials, meps, open data, open enterprise
26 October 2013
Tell Old Pharaoh: Let My Postcodes Go
The story of open data in the UK has been fairly uplifting in recent years, as more and more public datasets are released under liberal licences. Even the big holdouts - things like Ordnance Survey - have gradually loosened their grip. The same is true for the Postcode Address File (PAF), which has a surprising long history:
On Open Enterprise blog.
Posted by Glyn Moody at 1:36 pm 0 comments
Labels: open data, open enterprise, ordnance survey, postcodes
19 September 2013
EU Vote on Clinical Trials Data - Please Contact MEPs Now
I've written a few times about open data in the context of clinical trials - the information that must be provided when new drugs seek approval. As I noted, there is a growing movement to make such basic safety data freely available, the idea being that it could then be analysed by third parties, perhaps finding new applications of drugs, overlooked problems, or even wilful concealing of adverse effects.
On Open Enterprise blog.
Posted by Glyn Moody at 7:25 pm 0 comments
Labels: clinical trials, drugs, open data, open enterprise
18 September 2013
Reading Shakespeare: the Next Act of Open Data
As readers of this blog will have noticed, much of the most innovative work in the field of openness is taking place in open data. One of the largest stores of data is held by government, and the argument for opening it up where possible is strong: after all, we, the public, paid for this data, so it is only right that we, the public, should have access to it.
On Open Enterprise blog.
Posted by Glyn Moody at 7:50 pm 0 comments
Labels: open data, open enterprise, shakespeare, UK
European Court Puts Release Of Drug Safety Data On Hold
Last month Techdirt wrote about the case of the giant pharma company AbbVie seeking to prevent the European Medicines Agency from releasing basic health safety data that AbbVie claims contains commercially sensitive information. Unfortunately, an interim injunction has just been granted to that effect:
On Techdirt.
Posted by Glyn Moody at 12:21 pm 0 comments
Labels: clinical trials, ema, open data, techdirt
Open Data, Creative Destruction and Money
Nearly three years ago, I wrote an article exploring why at that time there were no billion-dollar companies (since then, Red Hat has finally broken through this barrier). Here's the key point:
On Open Enterprise blog.
Posted by Glyn Moody at 12:20 pm 0 comments
Labels: entrepreneurs, open data, open enterprise, open source, red hat
20 July 2013
Public Domain Human Genome Project Generated More Research And More Commercial Activity Than Proprietary Competitor
Traditionally, there has been a blithe assumption that more innovation occurs when patents are granted than when they are not. But as Techdirt has reported, people are finally beginning to call that into question. A forthcoming paper from an economist at MIT, Heidi Williams, provides another example of where that is not the case: in the field of genomics (via @gsDetermination).
On Techdirt.
Posted by Glyn Moody at 7:42 pm 0 comments
Labels: human genome project, open data, techdirt
Clinical Trials Must be Open Data: Please Contact MEPs
Back in February, I noted that the UK's investigation into making clinical trial data freely available was somewhat subsidiary to the EU's major initiative on the same subject. The battle there between those who wish to keep clinical trials data secret, for fear that it might show pharma companies in a bad light, and those who believe that it must be released to save money and - more importantly - save lives is now increasingly fierce.
On Open Enterprise blog.
Posted by Glyn Moody at 6:50 pm 0 comments
Labels: clinical trials, eu, meps, open data, open enterprise
14 April 2013
EU Proposal for (Nearly) Open Data [Update]
Update: Maël Brunet has pointed out that the press release I linked to below is from 2011; what was actually announced yesterday was that the EU Council's 'Coreper' committee (EU Committee of Member States' Permanent Representatives) has now endorsed the measures announced there. So, nothing has changed from what I wrote below, but another hurdle has been cleared in making the open data initiative happen. All that remains is for the European Parliament to agree, and the rules will come into force. Unfortunately, it seems unlikely that any amendments will be included at this stage, so it looks like we only get "almost" open data....
Posted by Glyn Moody at 2:50 pm 0 comments
Labels: european commission, open data, open enterprise, open source, open standards
31 March 2013
Open Source: That's the Way to Do It
Although the use of open source by the UK government has an unhappy history (and one that certainly isn't finished), one ray of hope comes from Gov.uk, as I've noted before. The driving force behind that site is the Government Digital Service (GDS), and on its blog there's a particularly interesting post by Mike Bracken, who rejoices in the splendid title of "Executive Director of Digital in the Cabinet Office."
On Open Enterprise blog.
Posted by Glyn Moody at 3:38 pm 0 comments
Labels: gov.uk, open data, open enterprise, open source, uk government
Giant Pharma Company Claims Releasing Data On Drug Safety Is Illegal As It's Confidential And 'Commercially Sensitive'
One of the initiatives gaining momentum around the world is open data -- the idea that, for example, non-personal data affecting the public should be made freely available. That's partly to improve transparency, so that citizens are more informed about what is happening, and partly to stimulate new kinds of business that build products and services based on that data.
On Open Enterprise blog.
Posted by Glyn Moody at 3:06 pm 0 comments
Labels: open data, pharma, techdirt, transparency
If It Comes With A Gagging Clause, It's Not Open Data
One of the richest seams of open data concerns transport. After all, by their very nature, transport systems generate huge amounts of new data every day -- times, routes, travel options. Similarly, huge numbers of people use multiple means of transport, which means there is a big potential audience for analyses of that data. And it's definitely in the interest of transport operators to make that information freely available so that developers can use it in new ways, since that is likely to make traveling easier, and lead to increased custom.
On Techdirt.
10 March 2013
Select Committee Inquiry into Clinical Trials Data
Back in November last year, I wrote about a particular class of open data - that regarding clinical trials data. I pointed out that of all open data, it is arguably the most important, because it can literally save lives - huge numbers of them. That post was by way of a taster for future columns - like this one - which touch on this area, since I believe it will become one of the most important battlegrounds for openness in the next few years.
On Open Enterprise blog.
Posted by Glyn Moody at 10:43 pm 0 comments
Labels: medicine, open data, open enterprise
The Continuing Disaster Of Open Government In Germany
Recently, Techdirt noted that the European "database right" could pose a threat to releasing public data there. But that assumes that central governments are at least trying to open things up. A splendid piece by Sebastian Haselbeck on the Open Gov Germany blog, with the self-explanatory title "German government screws up open data," underlines that things can fail because the government itself sabotages transparency moves.
On Techdirt.
09 March 2013
Europe's 'Database Right' Could Throttle Open Data Moves There
One of the more benighted moves by the European Union was the introduction of a special kind of copyright for databases in 1996: not for their contents, but for their compilation. This means that even if the contents are in the public domain, the database may not be. Thanks to a recent court judgment in France, this "database right" now threatens to become a real danger for the burgeoning open data movement in Europe (original in French).
On Techdirt.